Literature DB >> 7530595

Different angiogenic pathways characterize superficial and invasive bladder cancer.

T O'Brien1, D Cranston, S Fuggle, R Bicknell, A L Harris.   

Abstract

We have investigated by RNase protection analysis the expression of 2 angiogenic factors in 45 primary bladder tumors and 8 normal bladders. Expression of vascular endothelial growth factor (VEGF) was 3-fold higher and that of platelet-derived endothelial cell growth factor was 40-fold higher in tumors compared to normal bladder. However, the factors were differentially expressed in different stages of the cancer. Expression of VEGF in superficial tumors was 4-fold higher than in invasive tumors and 10-fold higher than in normal bladder (superficial versus invasive, P < 0.0006; superficial versus normal, P < 0.0002). Expression of platelet-derived endothelial cell growth factor in invasive tumors was 33-fold higher than in superficial tumors and 260-fold higher than in normal bladder (invasive versus superficial, P < 0.0001; invasive versus normal, P < 0.0003). In well differentiated or moderately differentiated superficial tumors which had invaded the lamina propria (pT1G1/2) VEGF expression was 4-fold higher in tumors which subsequently recurred at 3 months compared to those which did not recur (P < 0.002). Thus there are two distinct angiogenic pathways involved in different stages of bladder cancer, which is in keeping with the evidence for two different genetic pathways. Elevated VEGF expression predicts early recurrence of pT1G1/2 tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530595

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Thymidine phosphorylase expression in endometrial carcinomas.

Authors:  E Sivridis; A Giatromanolaki; M I Koukourakis; R Bicknell; A L Harris; K C Gatter
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

Review 3.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

Review 4.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

5.  Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.

Authors:  Tibor Szarvas; Tobias Jäger; Falk Droste; Markus Becker; Ilona Kovalszky; Imre Romics; Süleyman Ergün; Herbert Rübben
Journal:  Pathol Oncol Res       Date:  2008-09-20       Impact factor: 3.201

Review 6.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 7.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 8.  Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research.

Authors:  D J Brat; E G Van Meir
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 9.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 10.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.